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Introduction
During the last years, enormous progress has been made in
the ex vivomanufacture of human red blood cells (RBC). Using
human hematopoietic stem cells (HSC) from cord blood (CB)
or bone marrow as the primary source, expansion rates higher
than 105-fold,1-6 accompanied by fully terminal maturation into
enucleated reticulocytes,1-4 have been achieved. Recently, the
first proof-of-principle experiment was performed by transfus-
ing a small sample of manufactured RBC into a human recipi-
ent.7 However, despite this achievement, the large-scale expan-
sion of RBC for transfusion purposes (1 RBC unit contains 1012
RBC) remains problematic, as human HSC are a limited source.
Up to now, protocols for the ex vivo expansion of multipotent
HSC are not available. 
One promising alternative might be the generation of RBC
from human pluripotent stem cells, a theoretically unlimited
source characterized by properties of self-renewal. Until
recently, the ex vivo generation of RBC from human embryonic
stem cells (hESC) was limited by ethical concerns.
Furthermore, it is unknown whether any of the hESC lines
approved in the USA and produced under good manufacturing
practice conditions have the universal O Rhesus negative phe-
notype.8 These limitations were overcome by the discovery of
induced pluripotent stem cells (iPSC). Human iPSC, which
resemble hESC in vitro and in vivo, were initially generated from
fibroblasts through the ectopic expression of a combination of
the transcription factors OCT4, SOX2, KLF4, c-MYC as well as
NANOG and LIN28.9-11 Since these first studies, iPSC have been
derived from various tissues.12-16 Our group reported the gener-
ation of iPSC from human neural stem cells (NSC) by repro-
gramming with only OCT4 due to the cells’ endogenous
expression of pluripotency-associated genes.15
More recently, first protocols were established to induce
RBC development from human fibroblast-derived iPSC.17-22
However, in vitro recapitulation of physiological erythropoiesis
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Epigenetic memory in induced pluripotent stem cells, which is related to the somatic cell type of origin of the stem
cells, might lead to variations in the differentiation capacities of the pluripotent stem cells. In this context, induced
pluripotent stem cells from human CD34+ hematopoietic stem cells might be more suitable for hematopoietic dif-
ferentiation than the commonly used fibroblast-derived induced pluripotent stem cells. To investigate the influ-
ence of an epigenetic memory on the ex vivo expansion of induced pluripotent stem cells into erythroid cells, we
compared induced pluripotent stem cells from human neural stem cells and human cord blood-derived CD34+
hematopoietic stem cells and evaluated their potential for differentiation into hematopoietic progenitor and
mature red blood cells. Although genome-wide DNA methylation profiling at all promoter regions demonstrates
that the epigenetic memory of induced pluripotent stem cells is influenced by the somatic cell type of origin of the
stem cells, we found a similar hematopoietic induction potential and erythroid differentiation pattern of induced
pluripotent stem cells of different somatic cell origin. All human induced pluripotent stem cell lines showed termi-
nal maturation into normoblasts and enucleated reticulocytes, producing predominantly fetal hemoglobin.
Differences were only observed in the growth rate of erythroid cells, which was slightly higher in the induced
pluripotent stem cells derived from CD34+ hematopoietic stem cells. More detailed methylation analysis of the
hematopoietic and erythroid promoters identified similar CpG methylation levels in the induced pluripotent stem
cell lines derived from CD34+ cells and those derived from neural stem cells, which confirms their comparable ery-
throid differentiation potential. 
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ABSTRACT
in its entirety, which includes mesoderm induction, genera-
tion of HSC, erythroid maturation, hemoglobin switching
and enucleation, remains a challenge. Compared to the
established protocols for the adult system, RBC generation
from iPSC is less efficient. In addition to a poor expansion
rate of erythroid cells, the terminal differentiation of cells
generated ex vivo from iPSC fails, particularly with regards
to enucleation and switching from embryonic to fetal and
finally to adult hemoglobin.
Increasing evidence from murine23,24 and human sys-
tems25,26 indicates that iPSC exhibit an epigenetic memory
related to their donor cell type of origin. Although iPSC
show characteristics and behaviors of ESC, incomplete
removal of tissue-specific methylation or aberrant de novo
methylation has been observed, which might influence
their differentiation behavior. Due to this potential epige-
netic memory and its influence on hematopoietic differen-
tiation, iPSC from CD34+ HSC may be more suitable for
erythroid differentiation than the commonly used fibro -
blast-derived iPSC. 
To investigate the influence of an epigenetic memory on
the ex vivo expansion of iPSC into hematopoietic and ery-
throid cells, we generated iPSC lines from human CB-
derived CD34+ HSC and human NSC.15 We evaluated their
global gene methylation status and their potential to differ-
entiate into hematopoietic progenitors and mature RBC
under ex vivo conditions. Whereas CD34+ HSC are the phys-
iological source for RBC in humans and are of mesodermal
origin, NSC are derived from the ectodermal germ layer. For
the sake of completeness, fibroblast-derived iPSC27 and
hESC H1 were included in our study as “controls”.
Methods
Generation of human cord blood CD34+ induced 
pluripotent stem cells  
CD34+ HSC were isolated from human CB, using MACS sort-
ing (Miltenyi Biotec, Germany). Informed consent was obtained
from the donating mothers, and the investigation was approved
by the Ethics Committee of Heinrich-Heine-University
Düsseldorf Medical School. CD34+ cells were stimulated with
stem cell factor (SCF), thrombopoietin (TPO), fms-related tyro-
sine kinase 3 ligand (FLT3-L) and interleukin 6 (IL-6) as described
elsewhere28 and reprogrammed with either OCT4, SOX2, KLF4
and c-MYC or only OCT4 and SOX2. Lentiviral vectors encoding
the human cDNA of OCT4, SOX2, KLF4 and c-MYC under the
control of the SFFV promoter29,30 were produced as previously
described.15,31 Infected CD34+ cells were replated on irradiated
mouse embryonic fibroblast cells in ESC medium.
Approximately 25 days after transduction, iPSC colonies were
selected for further expansion on the basis of their morphology.
Established CD34+ iPSC lines were characterized as described
elsewhere.32 The generation and characterization of iPSC from
human NSC with OCT4 and KLF4 (NSC-2F-iPSC) or only OCT4
(NSC-1F-iPSC) by our group has already been published.15
Likewise, the generation of iPSC from human skin fibroblasts
(Fib-iPSC) with OCT4, SOX2, KLF4 and c-MYC has been
described.27 H1-hESC were obtained from WiCell (WI, USA). 
Global gene expression analysis 
RNA samples for microarray analysis were prepared using
RNeasy columns (Qiagen, Germany). The input in the linear
amplification protocol (Ambion) was 300 ng of total RNA per sam-
ple, with 12 h of in vitro transcription incorporating the biotin-
labeled nucleotides. Purified and labeled cRNA was hybridized
onto HumanHT-12 v4 expression BeadChips (Illumina, USA) fol-
lowing the manufacturer’s instructions. The chips were stained
with streptavidin-Cy3 (GE Healthcare) and scanned using the
iScan reader (Illumina). Methods for the microarray data process-
ing are available in the Online Supplement. 
Global DNA methylation analysis
Genomic DNA was extracted from human iPSC (passage ≥15)
and the corresponding somatic cell populations. The methylation
status of all promoter-associated CpG islands was analyzed.
Detailed methods are available in the Online Supplement. 
Hematopoietic and erythroid differentiation 
Human ESC H1 (n=6) and iPSC (n=4 respectively n=3 for NSC-
2F-iPSC, passages ≥15) were differentiated into hematopoietic cells
using the embryoid body method, as previously described18 (Figure
1, Table 1). Embryoid bodies were stimulated for 20 days with 100
ng/mL SCF, 100 ng/mL TPO, 100 ng/mL Flt3-L, 5 ng/mL IL-3, 5
ng/mL IL-6, 5 ng/mL vascular endothelial growth factor 165, BMP4
(20 ng/mL until day 9, then 10 ng/mL) (all from Peprotech, USA)
and 3 U/mL erythropoietin (EPO, Erypo®, Janssen-Cilag,
Germany). Day 21 embryoid bodies were dissociated into single
cells using collagenase B (0.4 U/mL; Roche Diagnostics,
Germany).33 For erythroid differentiation, single cells were cultured
for up to 25 days in Iscove liquid medium (Biochrom, Germany)
containing 10% human plasma (Octapharm, Germany), 10 μg/mL
insulin (Sigma Aldrich, Germany) and 330 μg/mL human holo-
transferrin (Spicac, UK). Cells were stimulated with the following
cytokines: day 0 to day 8: 100 ng/mL SCF, 5 ng/mL IL-3 and 3
U/mL EPO; day 8 to day 11: 100 ng/mL SCF and 3 U/mL EPO; day
11 to day 25: 3 U/mL EPO. 
Hematopoietic and erythroid development was monitored by
flow cytometry, colony formation in semisolid media and micro-
scopic evaluation of cell morphology. The hemoglobin composi-
tion was analyzed by high performance liquid chromatography
and polymerase chain reaction analysis. Detailed methods are
available in the Online Supplement.
Results 
Induction of pluripotency in human cord blood CD34+
hematopoietic stem cells
CD34+ HSC from human CB were reprogrammed to
pluripotency using lentiviral vectors expressing either
OCT4 and SOX2 alone (CD34-2F-iPSC) or expressing
OCT4, SOX2, KLF4 and c-MYC (CD34-4F-iPSC) as a poly-
cistronic unit under the control of the retroviral SFFV pro-
moter.29,30 The transduction efficiency of the CD34+ HSC
was approximately 70% and yielded different quantities of
ESC-like colonies, which were further propagated (Online
Supplementary Figure S1A). Immunofluorescence staining
was performed to detect the expression of the pluripotency
markers OCT4, NANOG, SSEA4, Tra1-60 and Tra1-81
(Online Supplementary Figure S1C,D) as well as alkaline
phosphatase staining (Online Supplementary Figure S1B).
Silencing of the SFFV promoter after reprogramming was
demonstrated by the absence of red fluorescent protein
expression in the iPSC colonies. This was further validated
using quantitative reverse transcriptase polymerase chain
reaction with vector-specific primers (Online Supplementary
Figure S1F). To evaluate their in vivo pluripotency, CD34+
iPSC were subcutaneously transplanted into mice with
severe combined immunodeficiency. Approximately 8
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weeks after injection, the CD34+ iPSC gave rise to ter-
atomas containing derivatives of all three germ layers,
including neural rosettes (ectoderm), smooth muscle and
chondrocytic elements (mesoderm) and gut-like structures
(endoderm) (Online Supplementary Figure S1E). 
Global gene expression profiling of human cord blood
CD34+ induced pluripotent stem cells 
To demonstrate successful reprogramming to pluripoten-
cy, global gene expression of CD34+ iPSC was compared to
the expression profile of hESC and the parental CD34+ pop-
ulation. The canonical pluripotency factors POU5F1/OCT4,
SOX2, LIN28, KLF4 and cMYC line up on the diagonal in
the pairwise scatter blot comparing the CD34+ iPSC and
H1-hESC (Figure 2A). It was found that 98.1% of the tran-
scripts were similarly expressed (using a 2-fold threshold in
log2 scale) in the CD34+ iPSC and H1-hESC. The distance
between the populations was reduced to 0.019, becoming
more than 3-fold closer relative to the parental CD34+ pop-
ulation, which demonstrates successful reprogramming to
pluripotency. Hierarchical clustering analysis showed that
CD34+ iPSC clustered closely with hESCs (H1 and H9) and
were distinct from parental CB CD34+ HSC (Figure 2B).
Similarly, principal component analysis demonstrated that
all CD34+ iPSCs clustered within the same 1st principal com-
ponent as the hESC and were distinct from their respective
parental CD34+ populations (Figure 2C).
Genome-wide DNA methylation profiling of human
induced pluripotent stem cells 
To evaluate epigenetic remodeling during reprogram-
ming, quantitative analysis of the methylation status of all
gene promoter-associated CpG islands was performed in
CB CD34+ iPSC, NSC iPSC,15 CB-derived unrestricted
somatic stem cells, iPSC and CB mesenchymal stromal cell
iPSC,32,34 as well as their respective starting cell populations.
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Figure 1. Experimental protocol for the ex vivo generation of hematopoietic and erythroid cells from human ESC and iPSC lines. To induce
hematopoietic commitment, undifferentiated hESC/iPSC were allowed to form embryoid bodies, which were stimulated for 21 days with a
cytokine cocktail, as indicated. For erythroid differentiation, day 21 embryoid bodies were digested into a single cell suspension and applied
to a three-phase liquid culture in the presence of growth factors for an additional 18 – 25 days. 
Table 1. Used cell lines, their origin and reprogramming factors.
Name                                                 Origin                Reprogramming
H1-hESC                                                                                                    
CD34-4F-iPS                                       CB CD34+ cells                     OCT4
                                                                                                               SOX2
                                                                                                               KLF4
                                                                                                               C-MYC
CD34-2F-iPS                                        CB CD34+ cells                     OCT4
                                                                                                                SOX2
NSC-2F-iPS15                                                 NSC                               OCT4
                                                                                                                KLF4
NSC-1F-iPS15                                                 NSC                               OCT4
Fib-iPS27                                                skin fibroblast                      OCT4
                                                                                                               SOX2
                                                                                                               KLF4
                                                                                                               C-MYC
A representative scatter plot comparing CD34+ iPSC with
their corresponding CD34+ HSC showed a similar distribu-
tion of the genes with higher and lower global methylation
patterns (Figure 2D). The hierarchical clustering analysis of
the global methylation patterns and the principal compo-
nent analysis revealed a clustering of all these iPSC with
their respective donor cell type of origin (Figure 2E,F). This
finding points to an epigenetic memory at the level of pro-
moter-associated CpG methylation of these iPSC. To focus
in more detail on hematopoietic gene loci, we evaluated
the CpG promoter methylation profiles for the hematopoi-
etic and erythrocyte development-associated genes CD34,
TAL1, KDR and T (Online Supplementary Figure S2), EPO,
GATA1, GATA2 (Online Supplementary Figure S3), the
hemoglobin clusters on chromosomes 11 and 16 (Online
Supplementary Figures S4 and S5), and HOXB4, CDX4 and
RUNX1 (Online Supplementary Figure S6). As a general
trend, we could not detect higher methylation levels for
the NSC iPSC compared with the CD34+ iPSC at the
hematopoietic loci analyzed. At the EPO and GATA2 loci
the methylation levels were lower in CD34+ iPSC than in
NSC iPSC (red versus blue bars in Online Supplementary
Figure S3).
Hematopoietic differentiation of human cord blood
CD34+ and neural stem cell induced pluripotent 
stem cells
Hematopoietic differentiation of iPSC (n=4 respectively
n=3 for NSC-2F-iPSC, passages ≥15) and H1-hESC (n=6)
was induced by embryoid body formation under cytokine
stimulation for 21 days. Flow cytometry analysis after
embryoid body digestion on day 21 (Figure 3A) demon-
strated the presence of 23%±17.3% CD43+ hematopoietic
cells from CD34-4F-iPSC and 18.6%±10.3% CD43+ cells
from NSC-2F-iPSC. The major fraction of these CD43+
cells consisted of CD45+/CD34– myeloid precursors
(CD34-4F-iPSC: 13.9%±6.7%; NSC-2F-iPSC:
14.6%±12.8%) expressing CD11, CD14 or CD15. Only a
minor subset consisted of CD45+/CD34+ hematopoietic
stem or progenitor cells (CD34-4F-iPSC 2.1%±0.9%; NSC-
Epigenetic memory in iPSC and erythropoiesis
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Figure 2. Global gene expression and epigenetic profiling of CB CD34+ iPSC and NSC iPSC. (A) Pairwise scatter plot of global gene expression
profile data comparing CD34+ iPSC and hESC (H1). Black lines indicate 2-fold changes in the gene expression levels between the paired cell
types. The positions of the pluripotent markers POU5F1/OCT4, SOX2, LIN28, KLF4 and cMYC are shown as orange circles. The gene expression
levels are log2 scaled. (B) Hierarchical clustering of global gene expression comparing CD34+ iPSC reprogrammed with OCT4, SOX2 (OS) or
OCT4, SOX2, KLF4 and cMYC (OSKM) and hESC (H9 and H1), as well as the CD34+ reprogramming starting populations. (C) Principal compo-
nent analysis of the global gene expression of CD34+ iPSC, their respective CD34+ HSC and hESC (H1 and H9). The first and second principal
components capture 83% and 7.9% of the sample population variability, respectively. (D) Pairwise scatter plot of the global methylation levels
comparing CD34+ iPSC and CD34+ HSC. (E) Hierarchical clustering analysis of the global methylation patterns at all gene promoter-associated
CpG islands of CD34+ iPSC, NSC iPSC, USSC iPSC and MSC iPSC as well as their respective somatic donor cell types of origin including CD34+
cells, NSC, USSC (cord blood unrestricted somatic stem cells) and MSC (cord blood mesenchymal stromal cells). (F) Principal component
analysis of the global methylation patterns at all gene promoter associated CpG islands of CD34+ iPSC, NSC iPSC, USSC iPSC, and MSC iPSC,
as well as their respective donor cell types of origin CD34+ cells, NSC, USSC and MSC. The first and second principal components capture 26%
and 18% of the sample population variability, respectively. 
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2F-iPSC: 2.7%±1%). Furthermore, a small population of
already differentiated GPA+/CD45– erythroid cells was
observed (CD34-4F-iPSC: 7.1%±10%; NSC-2F-iPSC:
3.6%±0.8%). Morphologically, these GPA+ cells were
already differentiated normoblasts and reticulocytes and,
therefore, without further impact in the erythroid differen-
tiation assay. In addition to GPA, the expression of CD36
(CD34-4F-iPSC: 11%±12.2%; NSC-2F-iPSC 6.3%±4%)
and CD71 was measured to identify more primitive ery-
throid cells (Figure 4C, day 0 of the erythroid differentia-
tion protocol). However, neither marker is specific for the
erythroid lineage.35,36 Independently of their hematopoietic
nature (measured by CD43), the majority of cells stained
positive for CD71 (CD34-4F-iPSC 63.4%±1.7%; NSC-2F-
iPSC: 62.5%±10.1%), indicating a high percentage of pro-
liferating cells with iron uptake, rather than of erythroid
progenitors. Comparable results regarding the hematopoi-
etic marker expression were observed for the CD34-2F-
iPSC, NSC-1F-iPSC, Fib-iPSC and H1-hESC (Figure 3A,B).
Colony formation assays demonstrated a similar colony
potential in the CD34-4F-iPS, NSC iPS and Fib-iPS cell lines
(1 colony/370 seeded cells), although the frequency of ery-
throid colonies was slightly higher in the CD34+ iPSC.
CD34-2F-iPSC gave rise to a lower total number of
colonies (Figure 3C,D). 
Erythroid differentiation of human cord blood CD34+
and neural stem cell induced pluripotent stem cells 
To address the terminal differentiation potential of iPSC
into mature RBC, unselected cells from dissociated day 21
embryoid bodies were cultured for an additional 21 to 25
days in an erythropoiesis assay (n=3 respectively n=4 for
CD34-4F-iPSC and NSC-1F-iPSC). During the first culture
days, non-hematopoietic cells continuously disappeared,
and by day 8, all of the cells were hematopoietic in nature.
The major fraction consisted of erythroid precursors as
determined by CD36 (CD34-4F-iPSC: 54.8%±14.7%; NSC-
2F-iPSC: 62.1%±1.6%) and GPA expression (CD34-4F-
iPSC: 66.4%±17.4%; NSC-2F-iPSC: 69.9%±17.5%) (Figure
4C). The remaining cells were mainly CD45+/GPA– myeloid
cells. At this time, independently of the iPSC/hESC line, the
majority of the erythroid cells showed morphological char-
acteristics of basophilic and polychromatic erythroblasts.
Until day 25, the cells further developed into a homogenous
population of erythroid cells (CD34-4F-iPSC: 99%±0.6%;
NSC-2F-iPSC: 98.6%±0.8%), showing characteristics of
normoblasts with small condensed nuclei and enucleated
reticulocytes (CD34-4F-iPSC: 27.3%±4.9%; NSC-2F-iPSC:
28.4±10.9%) (Figure 4B). In line with terminal differentia-
tion, CD36 expression decreased to 19.9%±9.5% in the
CD34-4F-iPSC and 19.7%±9.8% in the NSC-2F-iPSC. The
expression of CD71, the transferrin receptor, remained high
during the whole culture period. Comparable results were
achieved for erythroid differentiation of CD34-2F-iPSC,
NSC-1F-iPSC and Fib-iPSC. The terminal maturation and
enucleation rates were similar among all iPSC lines (Figure
4B,C). Scanning electron microcopy showed reticulocytes
with lobular phenotypes and occasionally mature RBC
with a biconcave shape (approximately 1:10-20 cells)
(Figure 4D). Interestingly, hESC differentiated more
homogenously into erythroid cells (day 8: 87.6%±3.5%
GPA+ erythroid cells), but the cells did not terminally
I. Dorn et al.
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Figure 3. Hematopoietic differentiation of human CB CD34+ iPSC and NSC iPSC. (A) Expression of hematopoietic markers on single cells from
dissociated day 21 embryoid bodies, as measured by flow cytometry (H1-hESC n=6, NSC-2F-iPSC n=3, NSC-1F-iPSC, CD34-2F-iPSC, CD34-4F-
iPSC and Fib-iPSC n=4). The bars represent the percentages (mean ± SD) of positive cells. (B) Representative flow cytometry analyses for
CD34 and CD45 expression on digested day 21 embryoid bodies from CD34-2F-iPSC that were reprogrammed with OCT4 and SOX2 and from
NSC-1F-iPSC that were reprogrammed with OCT4. (C) Hematopoietic colony formation in semisolid media after digestion of day 21 embryoid
bodies. The bars represent the mean number of erythroid and myeloid colonies that arose after 14 days from 30,000 digested, unselected
single cells. Additionally, the standard deviation (SD), with regards to the total number of colonies, is indicated in each cell line bar. (D)
Representative pictures for erythroid (BFU-E/CFU-E), myeloid (CFU-M/CFU-GM) and immature mixed (CFU-GEMM) colonies that arose from
CD34+-derived iPSC, scored after 14 days (original magnification 50-fold, bars represent 100 μm).
A B D
C
mature at the same rate. Although CD36 expression
decreased to the low level of 12.8%±10.9%, the percentage
of enucleated reticulocytes was only 7.9%±5.3%.
Morphological analysis showed larger cells with larger
nuclei and less compact chromatin (Figure 4B). 
Expansion of the erythroid cells reached its maximum
between day 15 and 18. Prolonged culturing resulted in the
death of the differentiated cells, associated with a decline
in cell number. The highest cell expansion rate was
observed in CD34-4F-iPSC with 1,368±461-fold expansion
calculated from the initial seeded CD34+/CD45+ cells; the
NSC-2F-iPSC underwent 635±165-fold expansion.
Considering that CD34– precursors might contribute to
erythroid development, we also calculated the number of
manufactured erythroid cells per 1,000 initially seeded uns-
elected single cells from day-21 embryoid bodies. The
highest erythroid outcome was observed in the CD34-4F-
iPSC with an average of 33x103 erythroid cells/103 seeded
cells of which approximately 9x103 were enucleated. This
was followed by the 2F-NSC-iPSC with an average of
18x103 erythroid cells/103 seeded cells of which 5x103 were
enucleated (Figure 4E). 
To determine the hemoglobin composition of the RBC
that were generated, high performance liquid chromatog-
raphy was performed during the final days of culture.
Independently of their somatic origin, all iPSC-derived
RBC contained mainly fetal hemoglobin (CD34-4F-iPSC:
89.4%±4.8%; NSC-2F-iPSC: 91%±1.8%; Fib-iPSC:
85.4%±7.7%) and to a lesser extent embryonic hemoglo-
bin (CD34-4F-iPSC: 6.9%±4.8%; NSC-2F-iPSC:
6.7%±1.9%; Fib-iPSC: 6.0%±0.9%) (Figure 5A,B). Only a
small amount of adult hemoglobin was detected (2%-7%).
In contrast, H1-hESC-derived RBC expressed equal
amounts of embryonic (49.1%±19.4%) and fetal
(50.2%±20.3%) hemoglobin. Adult hemoglobin was bare-
ly detectable (<1%). The high performance liquid chro-
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Figure 4. Erythroid differentiation of human CB CD34+ and NSC iPSC. (A) Pellet of ex vivo-generated erythroid cells from CD34+ iPSC, pho-
tographed on day 11 of the erythroid differentiation assay. (B) Representative pictures of cytospin preparations, prepared on day 18 of the
erythroid differentiation assay (original magnification 400-fold, scale bars represent 20 μm). For each cell line, the percentage of enucleated
RBC (mean ± SD) is indicated below the corresponding picture (n=3 respectively n=4 for CD34-4F-iPSC and NSC-1F-iPSC). (C) Cell surface
expression of CD45, CD36, CD71 and GPA during the erythroid differentiation protocol (additional 25 days after embryoid body digestion), as
measured by flow cytometry. The graphs represent the percentages (mean ± SD) of positive cells. (D) Scanning electron microscopy of ex vivo-
generated reticulocytes and biconcave shaped RBC from CD34+ iPSC, NSC iPSC and Fib-iPSC. The NSC-1F-iPSC-derived RBC is in contact with
an expelled nucleus. As a control, reticulocytes from healthy human cord blood, purified by selection of CD71+ cells, are shown (original mag-
nification 1,500-fold, scale bar represents 5 μm). (E) Cumulative number of erythroid cells (mean ± SD) generated during the erythroid differ-
entiation phase from 1,000 unselected single cells of digested day 21 embryoid bodies.
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matography results were confirmed by semiquantitative
polymerase chain reaction analyses for embryonic ε, fetal γ
and adult β-chains (Figure 5C).
Discussion
We report the successful generation of iPSC from human
CB CD34+ HSC and their differentiation into hematopoiet-
ic and erythroid cells. So far, protocols established for the
ex vivomanufacture of RBC from human fibroblast-derived
iPSC have failed to provide adequate expansion and termi-
nal differentiation, compared to the protocols for adult
HSC. Recent studies conducted with murine and human
systems indicated that iPSC have an epigenetic memory of
their somatic cell origin, which resulted in an impaired
hematopoietic differentiation potential of fibroblast, NSC
and keratinocyte-derived iPSC.23-26 This impairment in dif-
ferentiation was pronounced in early-passage iPSC lines
(<passage 10) and was attenuated at later passages (>pas-
sage 15).25 As a consequence of this potential epigenetic
memory and its influence on hematopoietic differentiation
pathways, CD34+ HSC may be more suitable than the
commonly used fibroblasts as a reprogramming starting
population to induce RBC generation from human iPSC.
To examine this issue further, we compared the
hematopoietic and erythroid development of two newly
established CD34+ iPSC lines with NSC-derived iPSC,
which were recently described by our group.15 Both popu-
lations are of fetal origin and can be classified as multipo-
tent, somatic stem cells. Whereas CD34+ HSC are the
physiological progenitors of RBC and are of mesodermal
origin, NSC are derived from the ectodermal germ layer. To
make our results more comparable with those of other
publications, we also included fibroblast-derived iPSC in
our study.27 Previously we demonstrated that multipotent
NSC are more amenable than unipotent fibroblasts to
reprogramming to iPSC.37 This observation was further val-
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Figure 5. Hemoglobin composition of ex vivo-generated erythroid cells. (A) Representative high performance liquid chromatographic (HPLC)
analyses, showing the tetrameric hemoglobin protein fractions in the ex vivo-generated erythroid cells from CD34+-iPSC, NSC iPSC, Fib iPSC,
H1-hESC, (day 18 of the erythroid differentiation phase) and in healthy human cord blood. Additionally, HPLC analysis of ex vivo-generated
erythroid cells from human adult CD34+ HSC, manufactured under the same culture conditions, is given (adult cRBC). The areas under the
curve represent the percentages of embryonic (embHb), fetal (HbF) and adult (HbA) hemoglobin with respect to the total amount of hemoglo-
bin. (B) Percentages (mean ± SD) of embryonic, fetal and adult hemoglobin obtained from HPLC analyses of H1-hESC, CD34+ iPSC, NSC iPSC
and Fib iPSC-derived erythroid cells (day 18 of the erythroid culture assay). Additionally, the hemoglobin composition of erythroid cells gener-
ated from human adult CD34+ HSC is given (adult cRBC). (C) Semiquantitative polymerase chain reaction analyses for the embryonic (ε), fetal
(γ) and adult (β) hemoglobin chains in ex vivo-generated erythroid cells from H1-hESC, NSC iPSC and CD34+ iPSC, as well as in erythroid cells
generated from adult CD34+ HSC (adult cRBC).
A
B C
idated with hematopoietic38 and endodermal39 cells. 
To analyze the epigenetic marks of the reprogrammed
cells, we performed genome-wide DNA methylation
analysis of various iPSC lines (all at passages >15) derived
from different sources (CD34+ HSC, NSC, mesenchymal
stromal cells and unrestricted somatic stem cells) being
aware that DNA methylation is just one parameter leading
to variations among iPSC lines.40 Our results indicate that
all iPSC have an epigenetic memory, as shown by their
global methylation profile at promoter regions. This was
confirmed by hierarchical clustering and principal compo-
nent analyses, demonstrating that all iPSC cluster together
with their corresponding somatic stem cells. 
For hematopoietic and erythroid differentiation, human
CD34+ HSC-, NSC- and fibroblast-derived iPSC (passages
>15) were applied to an embryoid body-based culture sys-
tem described recently.18 Despite the observed epigenetic
memory in global gene methylation, all iPSC lines per-
formed similarly in the initial hematopoietic induction,
independently of their somatic origin. The hematopoietic
commitment, analyzed by CD43 expression after 21 days
of cytokine-stimulated embryoid body formation, aver-
aged 20%, with some passage-dependent variations in
each cell line. This is consistent with the suggestions of
Bock et al.,41 who postulated, based on quantitative embry-
oid body differentiation assays, variations in differentiation
among iPSC lines within the normal spectrum of ESC vari-
ation. CD43 was recently identified as a hematopoiesis-
specific marker that is expressed in early hematopoietic
progenitors and persists in differentiating precursor cells.42
In line with others, we observed only a minor population
of CD45+/CD34+ or CD43+/CD34+ hematopoietic progeni-
tors (~2%).17-22,43 The vast majority of the CD43 hematopoi-
etic cells were already committed myeloid, megakaryocyte
and erythroid precursors. Additionally, the colony-forming
potential of the digested day 21 embryoid body cells was
not apparently different between the CD34+ iPSC, NSC
iPSC and Fib iPSC; only the frequency of erythroid
colonies was slightly higher in the CD34-4F-iPSC. 
iPSC from all sources gave rise to a homogeneous popu-
lation of erythroid cells at terminal stages of differentiation
(>96% GPA+ cells), exhibiting phenotypes of terminally
matured normoblasts, enucleated reticulocytes and, as
demonstrated by electron microscopy, occasionally bicon-
cave-shaped RBC. The percentage of enucleated cells
(21%-29%) and the preferential synthesis of fetal hemo-
globin (89%-96%) did not differ between the CB CD34+
iPSC, NSC iPSC and Fib-iPSC. However, although all the
iPSC lines were similar in their ability to terminally mature
into RBC, the expansion and final outcome of the erythroid
cells was slightly higher in the CD34+ iPSC (1,370-fold)
than in the NSC-iPSC (640-fold). This is in line with the
higher observed frequency of erythroid colony formation
in the CD34-4F-iPSC and might argue for a greater intrinsic
erythroid potential of these cells. 
Our results obtained from the iPSC contrast with those
observed for RBC generation from adult human HSC. For
comparison, the mean expansion of adult CD34+/CD45+
HSC (n=8), cultured under the same conditions, is 89,000-
fold, with homogeneous differentiation into enucleated
RBC (85.2%±4.8%) that express mainly adult hemoglobin
(unpublished data). When using CD34+ cells from CB, estab-
lished protocols with expansion rates of up to 1.96x106 fold
will theoretically allow for the generation of more than
3x1012 RBC from one CB unit.1 However, the erythroid dif-
ferentiation potential of the human iPSC described here is
similar to that in recent studies using fibroblast and mes-
enchymal stromal cell-derived iPSC in embryoid body18,21
or stromal layer-based culture systems.17,20 Although using
different culture conditions, all studies show a severely
limited expansion of the erythroid cells compared to that
from adult HSC, a low enucleation rate (<10%) and the
expression of mainly fetal and embryonic hemoglobin.
Compared to these results, we achieved a higher enucle-
ation rate (21-29% versus <10%17-22), which might be the
consequence of differences in the culture techniques or the
intrinsic characteristics of our iPSC cell lines. 
Because of the similar functionality of NSC and CB
CD34+-derived iPSC in hematopoietic and erythroid differ-
entiation, we focused the initial DNA methylation analysis
in more detail on promoter regions associated with
hematopoietic and erythroid differentiation pathways. We
did not detect higher methylation levels at many of the
hematopoietic-specific promoters in the NSC iPSC com-
pared to the CD34+ iPSC. A higher methylation level in
NSC iPSC, indicating impaired transcription of these
regions, could be considered a prerequisite for the pre-
ferred differentiation of CD34+ iPSC towards hematopoiet-
ic lineages. These results do, therefore, support the
observed similarity in hematopoietic and erythroid differ-
entiation in NSC iPSC and CD34+ iPSC. In addition to our
results, it would be very interesting to investigate the
hematopoietic potential and epigenetic marks of repro-
grammed erythroid progenitors further. The successful
reprogramming of erythroid progenitors derived from
patients with polycythemia vera has been described
recently.44
In a recent study our iPSC derived from mouse NSC
with OCT4 alone showed reduced neuronal and hemato-
endothelial differentiation compared to iPSC repro-
grammed with all four factors or ESC.45 This might be the
result of some epigenetic instability, as shown in the DNA
methylation pattern of the pluripotency associated pro-
moters, although their gene expression profile was very
similar to that of ESC.46 We can confirm these slight differ-
ences in the differentiation efficiency in human cells
depending on the number of reprogramming factors.
Although OCT4-derived (NSC) and OCT4/SOX2-derived
(CD34+ HSC) iPSC gave rise to similar percentages of
hematopoietic precursors compared to their corresponding
iPSC lines that were reprogrammed with more factors,
colony growth was impaired in CD34+ iPSC repro-
grammed with only OCT4/SOX2. Furthermore, the out-
come of the erythroid cells in the more specific erythro-
poiesis assays was likewise impaired in OCT4-induced
NSC iPSC and OCT4/SOX2-induced CD34+ iPSC.
Nevertheless, all iPSC lines gave rise to erythroid cells at
terminally mature stages, and the expansion rates were at
least as high as in H1-hESC. 
Although we can confirm our initial hypothesis of an epi-
genetic memory in CD34+ iPSC at higher passages on a
genome-wide level, this memory only marginally improved
the expansion and differentiation of RBC under ex vivo con-
ditions. RBC generation from iPSC does, therefore, still
remain a challenge, and major hurdles must be overcome
before iPSC-derived RBC will enter into clinical use. One
key issue for transfusion purposes will be large-scale ampli-
fication. Strategies to improve expansion rates might focus
on increased induction of early hematopoietic and ery-
throid progenitors from human iPSC and the maximization
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of their subsequent expansion (e.g. by controlled expression
of erythroid-specific genes, introduction of proliferation-
associated transcription factors,47,48 modification of growth
factor combinations or mimicry of endogenous niches).
Once all these difficulties have been successfully overcome,
ex vivo manufactured RBC from human iPSC might be used
for personalized transfusion medicine, preferentially
applied to allo-immunized patients or those with rare blood
groups. For these purposes, using CB CD34+ HSC as the
starting cell population, as described here, will have several
potential advantages: (i) CB CD34+ cells are of fetal origin
and have not been challenged by environmental influences
that lead to nuclear and mitochondrial mutations;49,50 (ii)
CD34+ HSC can be easily isolated from CB collected in an
already established worldwide network of CB banks, with-
out any donor risk;50 (iii) CB derived from CB banks will be
well characterized for immunological and infectious mark-
ers; and (iv) CB-derived iPSC would allow the formation of
CB iPSC banks to procure blood group-compatible RBC
units and, on demand, histocompatible cell transplants.
Furthermore, in newborns with congenital diseases, autolo-
gous CB might be readily available for the generation of
autologous cell products, disease modeling or genetic mod-
ifications.
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